I posted a similar post about six months ago. Most of the information I used at the time indicated that we are about to enter a period of potential announcements for POH. Some of the dates have been missed or are very close to being missed! I was hoping to get a picture into next year (when the current cash will run out if an unsuccessful arbitration outcome).
Any time now
– Mylan Arbitration Update - The main question that obviously hasn't be answered is have we won. The next question is how much but I would put a third less obvious question may be of significance. Why did the arbitrator give the June update announcement and then not follow through? An answer we have not been given and it would seem for no obvious reason. Could it be that Mylan and Poh are in discussions for a settlement and asked for no update to be given and we are currently in the middle of a legal to and fro?
Any time now +1 - The day after the Mylan arbitration or as part of the announcement, a decision should be revealed on the future of the daptomycin. It will be interesting here if Terumo plays a role. If POH needs to negotiate they hold a pretty strong hand due to their relationship with Terumo. I am sure Terumo with all their focus on injectables would be pretty happy to negotiate with POH.
August 2018
– Potential Roden-Fields announcement. At about this time Roden-Fields have had 8-9 months of developing mixtures as the started developing in December 2017. Hottod mentioned in discussions with Ross that these were progressing well. I am not sure how long it would take however given it takes 2 years for a injectable surely these mixtures must be less than a year.
September/October 2018
– The next injectable candidate should be announced. In the march newsletter it was outlined that Daptomycin is in late phase development, the second Propofol is progressing then the newsletter mentions a third (or possible multiple) unnamed leads with expectations for the 2
nd half of 2018. The list was pretty extensive including Clopidogrel, Tacrolimus, Vitamin K, Azithromycin etc. In the various presentations that Ross has given Clopidogrel looks like the most likely (IMO) based on the potential market indicators. Daptomycin, Propofol were the two largest and Clopidogrel was third.
October 2018
– Propofol announcement of POC clinical trials (Ross mentioned that Terumo is already in the toxicology stage with Propofol. On the 9/11/17 the announcement stated that the research collaboration had been in play for 15 months indicating the formulation stability stage. They indicated that animal studies conducted by Terumo would begin in 2017 and extend into 2018. This means that these studies have been undertaken for about 8 months (November to June). Given this stage usually last 12 months we can expect an announcement sometime in October.
December 2018
– FDA feedback on patches is set for December. Potentially very significant, could either revive the patches or this could be it for patches. If positive I suspect a partnership to be announced fairly quickly thereafter. Ross has mentioned that POH has had numerous discussions with potential partners.
December 2018
– It has been mentioned many times that feed companies are conducting due diligence on TPM. The earliest reference I could find was in March 2018. It seems three companies are investigating TPM, they started their own due diligence between December 2017 (the last references to animal feed in announcements) and March 2018. To put a timeline on it, the due diligence has been occurring for between 6-8 months. The trials POH conducted for poultry were 4 months, (broilers are 14 week old so that fits), the pigs are weaners which are generally removed 3-4 weeks of age. So the companies would well and truly have had long enough to do their due diligence. My time frame for December is based on the AGM where POH expect potential agreement with feed companies to have occurred by the end of December 2018 or early 2019. However I think it is pretty clear that if the companies were going to proceed they would know by know and the time between now and December would be to settle contracts? Tony Locatro (kudos to
@coppashaft) stated that RM was in queenstown recently - I speculate that maybe he was meeting
https://becfeedsolutions.co.nz/
October to December 2018
- Biolexar – Again thanks to Hottod we know that Pure Beauty is having some trouble with formulations and we also know that Ross has been assured that they are still interested in bringing it market.
March 2019
– Further Cash Raise as money will be low without significant improvement, major announcement or Mylan Payout. We know, from the investor presentation, that we have 12 months cash from June 2018 to June 2019. So in March/April a CR will be needed.
November 2019
– Propofol - RM mentioned in the AGM that it normally takes 2 years from stability to product being ready for market. Given we know the toxicology started in November 2017 we can expect the product coming to market in November 2019 (if we are still in existence!)
(20min delay)